RhumbLine Advisers
OLMA icon

RhumbLine Advisers’s Olema Pharmaceuticals OLMA Stock Holding History

RhumbLine Advisers’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
99,530
+15,180
+18% +$203K ﹤0.01% 2182
2026
Q1 		$1.26M Buy
84,350
+9,971
+13% +$222K ﹤0.01% 2079
2025
Q4 		$1.86M Sell
74,379
-9,910
-12% -$176K ﹤0.01% 1906
2025
Q3 		$825K Sell
84,289
-1,738
-2% -$10.4K ﹤0.01% 2361
2025
Q2 		$366K Buy
86,027
+27,972
+48% +$125K ﹤0.01% 2873
2025
Q1 		$218K Sell
58,055
-378
-0.6% -$1.9K ﹤0.01% 3062
2024
Q4 		$341K Buy
58,433
+572
+1% +$5.71K ﹤0.01% 2911
2024
Q3 		$691K Sell
57,861
-1,400
-2% -$17.9K ﹤0.01% 2490
2024
Q2 		$641K Buy
59,261
+17,953
+43% +$195K ﹤0.01% 2493
2024
Q1 		$468K Buy
41,308
+1,132
+3% +$14.6K ﹤0.01% 2702
2023
Q4 		$564K Buy
40,176
+2,336
+6% +$31.4K ﹤0.01% 2591
2023
Q3 		$467K Buy
37,840
+4,787
+14% +$48.8K ﹤0.01% 2650
2023
Q2 		$298K Buy
+33,053
New +$200K ﹤0.01% 3023
2022
Q2 		– Sell
-28,682
Closed -$122K – 3194
2022
Q1 		$122K Buy
28,682
+2,335
+9% +$12.9K ﹤0.01% 2850
2021
Q4 		$247K Sell
26,347
-160
-0.6% -$3.31K ﹤0.01% 2770
2021
Q3 		$731K Buy
26,507
+13,373
+102% +$361K ﹤0.01% 2372
2021
Q2 		$367K Buy
13,134
+2,168
+20% +$61.7K ﹤0.01% 2704
2021
Q1 		$364K Buy
+10,966
New +$470K ﹤0.01% 2630

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

RhumbLine Advisers's OLMA Position: Q2 2026 in Review

RhumbLine Advisers increased its Olema Pharmaceuticals (OLMA) stake by 18% in Q2 2026, buying an estimated $203K and bringing the position to 99,530 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2182.

RhumbLine Advisers first reported a position in OLMA in Q1 2021 and has held it in 18 quarters since. The position peaked at $1.86M in Q4 2025. 184 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • RhumbLine Advisers held 99,530 shares of Olema Pharmaceuticals worth $1.25M as of Q2 2026.
  • RhumbLine Advisers bought 15,180 Olema Pharmaceuticals shares in Q2 2026, an estimated $203K.
  • Olema Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2182 holding.
  • RhumbLine Advisers first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
  • RhumbLine Advisers's Olema Pharmaceuticals position peaked at $1.86M in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.